Last Updated 16 December 2014
In late age-related macular degeneration (AMD), vision deficits are noticeable, often debilitating, and can be a precursor to blindness. The availability of vascular endothelial growth factor (VEGF) inhibitor therapies delivered via intravitreal injection revolutionized the treatment of the wet form of late AMD (wet AMD) such that the majority of treated patients now maintain visual acuity. VEGF inhibitors will continue to dominate wet AMD treatment through the end of the 2013-2023 forecast period, but pipeline agents expected to launch and be incorporated into the treatment algorithm may bring about improved visual outcomes and/or a reduction in dosing frequency. Unlike wet AMD, no therapies are approved for treating late dry AMD, i.e., geographic atrophy (GA). The anticipated launch and subsequent uptake of first-to-market GA therapies toward the end of the study period is expected to have a dramatic effect on the AMD market, similar to the rapid market expansion observed upon the introduction of VEGF inhibitors into the treatment of wet AMD.